Federal Circuit Looks for a Different Kind of Unexpected Results in BMS v. Teva

02 July 2014 PharmaPatents Blog

In Bristol-Myers Squibb Co. v. Teva Pharmaceuticals USA, Inc., the Federal Circuit affirmed the district court’s finding that BMS’s Baraclude® patent is invalid as obvious. In so doing, the court gave little weight to unexpected results characterized as reflecting a difference in “degree” rather than a difference in “kind.” This decision joins other recent Federal Circuit decisions that have found unexpected results to be not unexpected enough to prevail against a strong showing of prima facie obviousness. 

The Patent at Issue

The patent at issue was BMS’s U.S. 5,206,244. The Federal Circuit decision focuses on claim 8, which recites the following compound:

[1S-(1α,3 α,4β)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylene-cyclopentyl]-6H-purin-6-one.

The ANDA Litigation

BMS markets the claimed compound as the hepatitis B drug Baraclude® (entecavir) for the treatment of hepatitis B. Teva filed an Abbreviated New Drug Application (ANDA) seeking to market a generic version of entecavir. In the ensuing Hatch-Waxman litigation, Teva asserted that the ‘244 patent was invalid as obvious and unenforceable due to inequitable conduct.

After a bench trial, the district court found that the patent was invalid as obvious. The court conducted a “lead compound” analysis, determined that 2’-CDG was a lead compound for the development of antiviral drugs at the filing date of the ‘244 patent, and found that the modification required to arrive at entecavir would have been obvious. Although the court found that BMS had presented objective evidence of nonobviousness (commercial success, long-felt need, and unexpected results), it “ultimately concluded that Teva proved by clear and convincing evidence that claim 8 would have been obvious.”

The Federal Circuit Decision

The Federal Circuit decision was authored by Judge Chen and joined by Chief Judge Prost and Judge Plager.

Much of the Federal Circuit opinion focuses on the “lead compound” analysis. Because that analysis is so fact-specific, I will not review it here. The section of the Federal Circuit decision that I find more interesting—and more troubling—is its treatment of BMS’s evidence of unexpected results. In particular, the opinion seems to set a high hurdle for establishing nonobviousness based on unexpected results unless the kind of results were unexpected.

The Federal Circuit transitions to this issue with this paragraph:

BMS also argues that a new chemical entity, as a matter of law, cannot be obvious when the claimed invention possesses unexpected properties. …. We have already rejected this argument en banc in [In re Dillon, 919 F.2d 688 (Fed. Cir. 1990)], explaining that an unexpected result or property does not by itself support a finding of nonobviousness.

The Federal Circuit cites Dillon for the principle that “additional unexpected properties … [do] not [necessarily] upset an already established motivation to modify a prior art compound based on the expected properties of the resulting compound.” The Federal Circuit explains:

Unexpected properties … do not necessarily guarantee that a new compound is nonobvious. While a “marked superiority” in an expected property may be enough in some circumstances to render a compound patentable, a “mere difference in degree” is insufficient. …. And “differences in degree” of a known and expected property are not as persuasive in rebutting obviousness as differences in “kind”—i.e., a new property dissimilar to the known property. When assessing unexpected properties, therefore, we must evaluate the significance and “kind” of expected results along with the unexpected results. ….

The Federal Circuit considered the three kinds of unexpected results cited by BMS, “(1) high potency against hepatitis B, (2) a larger than expected therapeutic window, and (3) a high genetic barrier to resistance,” and determined that record supported the district court’s finding that the first two properties were “not entirely unexpected” based on what already was known about 2’-CDG. The Federal Circuit did not disturb the district court’s finding that the third kind of result was unexpected, such that there was “some support to BMS’s argument as to nonobviousness.” Still, the Federal Circuit did not disturb the district court’s ultimate finding of obviousness:

We agree with the factual findings on secondary considerations and find no clear error. As stated previously, we also agree with the district court’s finding that the record demonstrates strong evidence of obviousness. After considering all of the findings for and against obviousness, as well as Teva’s burden of proof, we see no basis to disturb the district court’s ultimate legal conclusion, and we affirm the judgment that claim 8 of the ’244 patent is invalid as obvious.

A Different Kind of Unexpected Results?

The principle that results that are different in kind from those of the prior art are more “unexpected” than results that are different in degree is not new, but this decision still concerns me because entecavir was found to exhibit an unexpected property, as well as exhibiting greater anti-viral activity and having a broad therapeutic window. As a patent attorney and potential patient, I am concerned that too many new drugs will be found obvious in hindsight, eventually discouraging the tremendous investment required to discover and develop improved therapies.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services

Insights

CMS Proposes Enhanced Scrutiny over Medicaid Supplemental Payments
20 November 2019
Health Care Law Today
The Purpose of a Corporation
November 2019
Legal News: Business Law
Should This Be a "Mobility" Industry Blog?
19 November 2019
Dashboard Insights
Data Processing Patent Eligibility: Federal Circuit Finds Claims Eligible in KPN v. Gemalto
19 November 2019
IP Litigation Current
PATH Summit 2019
18-20 December 2019
Arlington, VA
Madison CLE Days
18-19 December 2019
Madison, WI
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
HFMA MA-RI Annual Compliance Update
12 December 2019
Boston, MA